On the 3rd, the US FDA announced the approval of the listing of the CD38 antibody Sarclisa (isatuximab-irfc) developed by Sanofi (Sanofi) for use in combination with pomalidomide and dexamethasone to treat adult multiple myeloma (MM) Patient...